新型真菌Cyp51抑制剂VT-1598对多种真菌的体外活性
VT-1598是一种对真菌Cyp51特异性更高的新型四唑类抗真菌药,体外试验显示其对念珠菌、隐球菌、地方性真菌、曲霉及 arrhizus 根霉的活性与现有抗真菌药相当或更强,且对耐药菌株仍保持活性。
要点
- VT-1598对念珠菌、隐球菌、地方性真菌、曲霉和根霉均有体外活性。
- 对氟康唑耐药念珠菌等耐药株仍保持体外活性。
- 需进一步体内研究评估其疗效。
核心结论
- VT-1598对酵母、霉菌和地方性真菌具有体外活性,且对其它抗真菌药敏感性降低的菌株仍保持活性。
- 需进一步研究评估VT-1598对不同真菌病原体的体内疗效。
研究设计与样本
- 采用CLSI标准的肉汤微量稀释法或宏量稀释法进行抗真菌药敏试验。
- 使用各菌种的临床分离株,并测试临床可用的抗真菌药物作为对照。
主要发现
- VT-1598对酵母和霉菌的体外活性与临床可用抗真菌药相似或更强,包括两性霉素B、氟康唑、卡泊芬净、伏立康唑和泊沙康唑。
- VT-1598对耐药分离株(包括氟康唑耐药念珠菌)的体外活性得以保持。
- VT-1598对地方性真菌(包括芽生菌、组织胞浆菌以及球孢子菌的两种)也观察到体外活性。
临床怎么用
- VT-1598作为新型四唑类,对真菌Cyp51特异性更高,潜在临床显著药物相互作用减少。
- 体外活性提示其可能覆盖耐药真菌,但临床使用需待体内疗效研究确认。
局限性
- 本研究仅评估体外活性,未涉及体内疗效。
- 未报告具体抑菌浓度数值、样本量及统计比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive fungal infections, including those caused by yeasts, moulds and endemic organisms, can be significant causes of morbidity and mortality in immunocompromised hosts, those with multiple comorbidities and occasionally immunocompetent hosts. Current antifungal agents are often limited by drug toxicities, drug interactions or the development of resistance. VT-1598 is a novel tetrazole that has greater specificity for fungal Cyp51 than currently available triazoles and thus the potential for clinically significant drug interactions is reduced. We measured the in vitro activity of VT-1598 against clinical isolates of Candida and Cryptococcus species, endemic fungi, including Coccidioides, Blastomyces and Histoplasma, Aspergillus species and Rhizopus arrhizus. METHODS: Antifungal susceptibility testing was performed by broth microdilution or macrodilution methods per CLSI standards. Clinical isolates of each species were used and clinically available antifungal agents were tested against each isolate. RESULTS: VT-1598 demonstrated in vitro activity against yeasts and moulds that was similar to or greater than that of clinically available antifungal agents, including amphotericin B, fluconazole, caspofungin, voriconazole and posaconazole. The in vitro activity of VT-1598 was also maintained against resistant isolates, including fluconazole-resistant Candida isolates. In vitro activity was also observed against endemic fungi, including Blastomyces, Histoplasma and both Coccidioides immitis and Coccidioides posadasii. CONCLUSIONS: VT-1598 demonstrated in vitro activity against yeasts, moulds and endemic fungi, which was maintained against isolates that had reduced susceptibility to other antifungals. Further studies are warranted to evaluate the in vivo efficacy of VT-1598 against various fungal pathogens.
引用
- Wiederhold NP, Patterson HP, Tran BH, et al. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus. J Antimicrob Chemother. 2018. PMID: 29190379. doi:10.1093/jac/dkx410
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。